Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.6.99.1 (
NADPH-diaphorase
)
3,903
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Huntington's disease is a genetic disorder that results from degeneration of striatal neurons, particularly those containing GABA (gamma-aminobutyric acid). There is no effective treatment for preventing or slowing this neuronal degeneration.
Ciliary neurotrophic factor
(
CNTF
) is a trophic factor for striatal neurons and therefore a potential therapeutic agent for Huntington's disease. Here we evaluate
CNTF
as a neuroprotective agent in a nonhuman primate model of Huntington's disease. We gave cynomolgus monkeys intrastriatal implants of polymer-encapsulated baby hamster kidney fibroblasts that had been genetically modified to secrete human
CNTF
. One week later, monkeys received unilateral injections of quinolinic acid into the previously implanted striatum to reproduce the neuropathology seen in Huntington's disease. Human
CNTF
was found to exert a neuroprotective effect on several populations of striatal cells, including GABAergic, cholinergic and
diaphorase
-positive neurons which were all destined to die following administration of quinolinic acid. Human
CNTF
also prevented the retrograde atrophy of layer V neurons in motor cortex and exerted a significant protective effect on the GABAergic innervation of the two important target fields of the striatal output neurons (the globus pallidus and pars reticulata of the substantia nigra). Our results show that human
CNTF
has a trophic influence on degenerating striatal neurons as well as on critical non-striatal regions such as the cerebral cortex, supporting the idea that human
CNTF
may help to prevent the degeneration of vulnerable striatal populations and cortical-striatal basal ganglia circuits in Huntington's disease.
...
PMID:Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. 912 55
Neurotrophin-3 (NT-3) is known to promote enteric neuronal and glial development.
Ciliary neurotrophic factor
(
CNTF
) and leukemia inhibitory factor (LIF) were investigated to test the hypothesis that the development of subsets of enteric neurons and/or glia is also affected by a neuropoietic cytokine, by itself, or together with NT-3. Crest-derived cells, immunoselected from the fetal rat gut (E14) with antibodies to p75NTR, were found by RT-PCR and immunocytochemistry (after culture) to express both alpha (CNTER alpha) and beta components (gp130 and LIFR beta) of the tripartite CNTF receptor. In situ, myenteric ganglia below the esophagus were CNTFR alpha-immunoreactive by E16-E18. In vitro,
CNTF
and LIF induced in crest-derived cells nuclear translocation of STAT3 (signal transducer and activator of transcription 3), a concentration-dependent increase in expression of neuronal or glial markers, and a decrease in expression of the precursor marker, nestin. LIFR beta was expressed by more cells than CNTFR alpha; therefore, although the factors were equipotent, the maximal effect of LIF >
CNTF
. The cytokines and NT-3 were additive in promoting neuronal but not glial development. Specifically, the development of neurons expressing
NADPH-diaphorase
activity (an early marker found in inhibitory motor neurons) was promoted by
CNTF
and NT-3. These observations support the idea that a ligand for the tripartite CNTF receptor complex plays a role in ENS development.
...
PMID:Promotion of the development of enteric neurons and glia by neuropoietic cytokines: interactions with neurotrophin-3. 965 38